Compare Biogen Inc (BIIB) vs MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? Biogen Inc trades at $210.65 (market cap $30.86B), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $34. Which is the better fit depends on your goals.
| BIIB | FNGU | |
|---|---|---|
Market Cap | $30.86B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $216.63 | $36.15 |
52-Week Low | $132.22 | $13.73 |
Enterprise Value | $37.93B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $210.65, up 3.32% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 37.1 and net income margin of 8.32%, supported by positive cash flow trends. Recent news highlights the acquisition of RayThera Inc. and raised 2026 guidance, reflecting strategic growth initiatives.
Outlook is positive with analyst consensus price target of $234.47, though risks include competitive pressures and earnings volatility. Investment opportunity lies in pipeline expansion and Alzheimer's drug traction, balanced by margin compression concerns from legacy MS portfolio declines.
FNGU, a 3X leveraged ETN tracking FANG+ stocks, trades at $32.19, down 1.62% on the day. Technical indicators show a bullish trend with moving averages supporting upside, but RSI levels above 70 suggest overbought conditions. Recent news highlights extreme volatility, with a 16% single-day loss reported on June 5, 2026 (24/7 Wall Street).
The outlook remains high-risk due to leverage amplifying moves; potential for rapid gains exists if tech rallies, but structural decay and volatility erosion pose severe risks. Investors must understand the product's design, as hidden costs beyond the 0.95% fee can significantly impact returns over time.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →
